Você procurou por: mdi (Inglês - Maltês)

for mdi:
għall-mdi:

methyldiphenyl diisocyanate (mdi)
metilindifenil diisoċjanat (mdi)

appropriate ppe sold with products containing mdi
ppe xieraq mibjugħ mal-prodotti li fihom mdi

appropriate use instructions on products containing mdi
istruzzjonijiet ta’ użu supplimentari tal-prodotti li fihom l-mdi

further health data are requested in the case of preparations containing mdi.
qiegħed jintalab aktar tagħrif dwar is-saħħa fil-każ ta’ preparazzjonijiet li jkunu jinkludu l-mdi.

high: the risks from mdi products to consumers would be eliminated.
għolja: ir-riskji mill-prodotti mdi lill-konsumaturi jitneħħew.

mdi = hydrocarbon mass emission for diurnal test (grams),
mdi = emissjoni ta' piż ta' idrokarburi għal test ta' matul il-ġurnata (grammi),

mdi is mainly used in the industrial production of rigid polyurethane foams with world wide use.
l-mdi jintuża prinċipalment fil-produzzjoni industrijali tal-foams riġidi tal-polyurethane mad-dinja kollha.

consumers can reduce dermal exposure and will be well informed to avoid misuse during the application of mdi products.
il-konsumaturi jistgħu jnaqqsu l-espożizzjoni għall-ġilda u se jkunu mgħarrfa tajjeb biex jevitaw l-użu ħażin tul l-applikazzjoni tal-prodotti mdi.

a human health risk reduction strategy for mdi was prepared by ecolas on behalf of the belgian rapporteur in november 2004.
strateġija għat-tnaqqis tar-riskju għas-saħħa umana għall-mdi ġiet ippreparata mill-ecolas f’isem ir-relatur belġjan f’novemru ta’ l-2004.

however, as with preparations including mdi, the physical characteristics of the products marketed significantly limit the risks.
madankollu, bħal fil-preparazzjonijiet li jinkludu l-mdi, il-karatteristiċi fiżiċi tal-prodotti mibjugħa jillimitaw ir-riskji b’mod sinifikanti.

a requirement to add polyethylene gloves and specific warnings and use instructions to all products containing mdi sold to the general public are effective and efficient measure to reduce the health risks to consumers.
rekwiżit biex jiżdiedu ingwanti tal-polyethylene u twissijiet speċifiċi u struzzjonijiet għall-użu tal-prodotti kollha li fihom id-dmi mibjugħin lill-pubbliku inġenerali huma miżuri effettivi u effiċjenti għat-tnaqqis tar-riskji għas-saħħa tal-konsumaturi.

a study was conducted by bipro on behalf of the belgian rapporteur in june 2006, on the advantages and drawbacks of various possible measures restricting the marketing and use of mdi.
Ġie konkluż studju mill-bipro f’isem ir-relatur belġjan f’Ġunju 2006, dwar il-vantaġġi u l-iżvantaġġi ta’ diversi miżuri possibbli li jillimitaw it-tqegħid fis-suq u l-użu ta’ l-mdi.

during the limitations working group meetings, the member states competent authorities, the stakeholder and the commission agreed that a study to collect more data on possible cases of respiratory allergy due to products containing mdi.
matul il-laqgħat tal-grupp ta’ Ħidma għal-limitazzjonijiet, l-awtoritajiet kompetenti ta’ l-istati membri, il-partijiet interessati u l-kummissjoni ftehmu li għandu jsir studju biex tinġabar aktar data f’każijiet possibbli ta’ allerġiji respiratorji minħabba l-prodotti li fihom l-mdi.

(6) natural or legal persons placing on the market for the first time preparations containing mdi shall, within 3 years from the date of implementation of the restrictions set forth in paragraph (1), collect data on possible cases of persons suffering from respiratory allergy during the use of preparations containing mdi and make those data available to the commission.
(6) persuni naturali jew legali li jpoġġu għall-ewwel darba fis-suq preprazzjonijiet li fihom l-mdi għandhom, sa 3 snin mid-data ta’ l-implimentazzjoni tar-restrizzjonijiet stabbiliti fil-paragrafu (1), jiġbru data dwar każijiet possibbli ta’ persuni li jbatu minn allerġija respiratorja matul il-preparazzjonijiet li fihom l-mdi u jpoġġu din id-data għad-dispożizzjoni tal-kummissjoni.